Martin C. Gregory

Martin C. Gregory, MD, PhD

Languages spoken: English, French

Clinical Locations

Kidney & Liver Clinic

Kidney and Liver Clinic
Salt Lake City
801-581-2772

  • Martin Gregory, MD, PhD is a Clinical Professor of Medicine at the University of Utah School of Medicine. As a nephrologist, his clinical interests include general nephrology and hereditary renal diseases.

    Dr. Gregory received his BM, BCh and DPhil Degrees (MD, PhD equivalents) from Oxford University. He received training in medicine and nephrology from the University of Otago, New Zealand, and Oxford University. He completed his residency at the University of London and at Oxford University, then fellowship in nephrology at Oxford University. He received further nephrology training at the University of Paris (VI). Dr. Gregory is board certified in Internal Medicine and Nephrology. In the past, Dr. Gregory served as Chief of Nephrology at Groote Schuur Hospital, Cape Town, South Africa and as Director of Dialysis Services, Bermuda Hospitals Board, Bermuda. He is currently a member of the Medical Advisory Board of the Alport Syndrome Foundation and a member of the Medical Advisory Board of the National Kidney Foundation of Utah and Idaho.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Nephrology)

  • Martin Gregory, MD, PhD is a Clinical Professor of Medicine at the University of Utah School of Medicine. As a nephrologist, his clinical interests include general nephrology and hereditary renal diseases.

    Dr. Gregory received his BM, BCh and DPhil Degrees (MD, PhD equivalents) from Oxford University. He received training in medicine and nephrology from the University of Otago, New Zealand, and Oxford University. He completed his residency at the University of London and at Oxford University, then fellowship in nephrology at Oxford University. He received further nephrology training at the University of Paris (VI). Dr. Gregory is board certified in Internal Medicine and Nephrology. In the past, Dr. Gregory served as Chief of Nephrology at Groote Schuur Hospital, Cape Town, South Africa and as Director of Dialysis Services, Bermuda Hospitals Board, Bermuda. He is currently a member of the Medical Advisory Board of the Alport Syndrome Foundation and a member of the Medical Advisory Board of the National Kidney Foundation of Utah and Idaho.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Nephrology & Hypertension
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Nephrology)

    Education history

    Residency Neurology - Churchill Hospital Resident
    Nephrology - Hopital Necker Resident
    Doctoral Training University of Oxford Ph.D.
    Nephrology - Radcliffe Infirmary Fellow
    Fellowship Neph-Hypertension - Churchill Hospital Fellow
    Internal Medicine - Hammersmith Resident
    Internship General Medicine/Surgery - Radcliffe Infirmary Intern
    Physiology - University of Oxford M.A.
    Professional Medical Medicine - University of Oxford M.D.
    University of Oxford B.A.
    Undergraduate Premedical Sciences - University of Otago B.Med.Sciences

    Selected Publications

    Journal Article

    1. Savige J, Lipska-Zietkiewicz BS, Watson E, Hertz JM, Deltas C, Mari F, Hilbert P, Plevova P, Byers P, Cerkauskaite A, Gregory M, Cerkauskiene R, Ljubanovic DG, Becherucci F, Errichiello C, Massella L, Aiello V, Lennon R, Hopkinson L, Koziell A, Lungu A, Rothe HM, Hoefele J, Zacchia M, Martic TN, Gupta A, van Eerde A, Gear S, Landini S, Palazzo V, Al-Rabadi L, Claes K, Corveleyn A, Van Hoof E, van Geel M, Williams M, Ashton E, Belge H, Ars E, Bierzynska A, Gangemi C, Renieri A, Storey H, Flinter F (2021). Guidelines for Genetic Testing and Management of Alport Syndrome. Clin J Am Soc Nephrol, 17(1), 143-154. (Read full article)
    2. Savige J, Storey H, Watson E, Hertz JM, Deltas C, Renieri A, Mari F, Hilbert P, Plevova P, Byers P, Cerkauskaite A, Gregory M, Cerkauskiene R, Ljubanovic DG, Becherucci F, Errichiello C, Massella L, Aiello V, Lennon R, Hopkinson L, Koziell A, Lungu A, Rothe HM, Hoefele J, Zacchia M, Martic TN, Gupta A, van Eerde A, Gear S, Landini S, Palazzo V, Al-Rabadi L, Claes K, Corveleyn A, Van Hoof E, van Geel M, Williams M, Ashton E, Belge H, Ars E, Bierzynska A, Gangemi C, Lipska-Zitkiewicz BS (2021). Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria. Eur J Hum Genet, 29(8), 1186-1197. (Read full article)
    3. Ahmed F, Kamae KK, Jones DJ, Deangelis MM, Hageman GS, Gregory MC, Bernstein PS (2013). Temporal macular thinning associated with X-linked Alport syndrome. JAMA Ophthalmol, 131(6), 777-82. (Read full article)
    4. Kashtan CE, Ding J, Gregory M, Gross O, Heidet L, Knebelmann B, Rheault M, Licht C (2013). Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatr Nephrol, 28(1), 5-11. (Read full article)
    5. Bekheirnia MR, Reed B, Gregory MC, McFann K, Shamshirsaz AA, Masoumi A, Schrier RW (2010). Genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol, 21(5), 876-83. (Read full article)
    6. Pont-Kingdon G, Sumner K, Gedge F, Miller C, Denison J, Gregory M, Lyon E (2009). Molecular testing for adult type Alport syndrome. BMC Nephrol, 10, 38.
    7. Gregory, MC (2009). Cost-Effective Dialysis for the Developing World. Ethn Dis, 19(Spring), S1 65-67.
    8. Gregory MC (2009). Cost-effective dialysis for the developing world. Ethn Dis, 19(1 Suppl 1), S1-65-7. (Read full article)
    9. Gross O, Borza D-B, Anders H-J, Licht C, Weber M, Segerer S, Torra R, Gubler M-C, Heidet L, Harvey S, Cosgrove D, Lees G, Kashtan C, Gregory M, Savige J, Ding J, Thorner P, Abrahamson DR, Antignac C, Tryggvason K, Hudson B, Miner JH (2009). Stem cell therapy for Alport syndrome: the hope beyond the hype*. Nephrol Dial Transplant, 24, 731-734.
    10. Gross O, Borza DB, Anders HJ, Licht C, Weber M, Segerer S, Torra R, Gubler MC, Heidet L, Harvey S, Cosgrove D, Lees G, Kashtan C, Gregory M, Savige J, Ding J, Thorner P, Abrahamson DR, Antignac C, Tryggvason K, Hudson B, Miner JH (2009). Stem cell therapy for Alport syndrome: the hope beyond the hype. Nephrol Dial Transplant, 24(3), 731-4. (Read full article)
    11. Pont-Kingdon G, Sumner K, Gedge F, Miller C, Denison J, Gregory M, Lyon E (2009). Molecular testing for adult type Alport syndrome. BMC Nephrol, 10, 38. (Read full article)
    12. Alverson DC, Saiki SM Jr, Caudell TP, Goldsmith T, Stevens S, Saland L, Colleran K, Brandt J, Danielson L, Cerilli L, Harris A, Gregory MC, Stewart R, Norenberg J, Shuster G, Panaoitis, Holten J 3rd, Vergera VM, Sherstyuk A, Kihmm K, Lui J, Wang KL (2006). Reification of abstract concepts to improve comprehension using interactive virtual environments and a knowledge-based design: a renal physiology model. Stud Health Technol Inform, 119, 13-8. (Read full article)
    13. Zehnder AF, Adams JC, Santi PA, Kristiansen AG, Wacharasindhu C, Mann S, Kalluri R, Gregory MC, Kashtan CE, Merchant SN (2005). Distribution of type IV collagen in the cochlea in Alport syndrome. Arch Otolaryngol Head Neck Surg, 131(11), 1007-13. (Read full article)
    14. Gregory MC (2005). The clinical features of thin basement membrane nephropathy. Semin Nephrol, 25(3), 140-5. (Read full article)
    15. Zehnder AF, Adams JC, Santi PA, Kristiansen AG, Washarasindhu C, Mann S, Kalluri R, Gregory MC, Kashtan CE, Merchant SN (2005). Distribution of tiype IV collagen in the cochlea in Alport syndrome. Arch Otolaryngol Head Neck Surg, 131(11), 1007-13.
    16. Parr CJ, Miller FJ, Gregory MC, Yoon HC (2004). SIR 2004 film panel case: Primary hyperoxaluria type I mimicking arterial vasculitis--a lethal disease. J Vasc Interv Radiol, 15(9), 1017-20. (Read full article)
    17. Merchant SN, Burgess BJ, Adams JC, Kashtan CE, Gregory MC, Santi PA, Colvin R, Collins B, Nadol JB Jr (2004). Temporal bone histopathology in alport syndrome. Laryngoscope, 114(9), 1609-18. (Read full article)
    18. Parr CJ, Miller FJ, Gregory MC, Yoon HC (2004). SIR 2004 Film panel case: Primary hyperoxaluria type I mimicking arterial vasculitis--a lethal disease. J Vasc Interv Radiol, 15(9), 1017-20.
    19. Merchant SN, B urgess B J, Adams JC, Kashtan CE, Gregory MC, Santi PA, Colvin R Colns B, Nadol JB Jr (2004). Temporal bone histopathology in Alport syndrome. Laryngoscope, 114(9), 1609-18.
    20. Heath KE, Campos-Barros A, Toren A, Rozenfeld-Granot G, Carlsson LE, Savige J, Denison JC, Gregory MC, White JG, Barker DF, Greinacher A, Epstein CJ, Glucksman MJ, Martignetti JA (2001). Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. Am J Hum Genet, 69(5), 1033-45. (Read full article)
    21. Barker DF, Denison JC, Atkin CL, Gregory MC (2001). Efficient detection of Alport syndrome COL4A5 mutations with multiplex genomic PCR-SSCP. Am J Med Genet, 98(2), 148-60. (Read full article)
    22. Florell SR, Egan CA, Gregory MC, Zone JJ, Petersen MJ (2001). Eosinophilic fasciitis occurring four weeks after the onset of dialysis in a renal failure patient. J Cutan Med Surg, 5(1), 33-6. (Read full article)
    23. Haas LJ, Gregory MC (2000). Teaching behavior change skills to first-year medical students: a small group experiential approach. Educ Health (Abingdon), 13(3), 337-45. (Read full article)
    24. Flanigan KM, Bromberg MB, Gregory M, Baringer JR, Jones CR, Nester TA, Klatt EC, Townsend JJ (1998). Calciphylaxis mimicking dermatomyositis: ischemic myopathy complicating renal failure. Neurology, 51(6), 1634-40. (Read full article)
    25. Martin P, Heiskari N, Zhou J, Leinonen A, Tumelius T, Hertz JM, Barker D, Gregory M, Atkin C, Styrkarsdottir U, Neumann H, Springate J, Shows T, Pettersson E, Tryggvason K (1998). High mutation detection rate in the COL4A5 collagen gene in suspected Alport syndrome using PCR and direct DNA sequencing. J Am Soc Nephrol, 9(12), 2291-301. (Read full article)
    26. Sasaki S, Zhou B, Fan WW, Kim Y, Barker DF, Denison JC, Atkin CL, Gregory MC, Zhou J, Segal Y, Sado Y, Ninomiya Y, Michael AF, Kashtan CE (1998). Expression of mRNA for type IV collagen alpha1, alpha5 and alpha6 chains by cultured dermal fibroblasts from patients with X-linked Alport syndrome. Matrix Biol, 17(4), 279-91. (Read full article)
    27. Barker DF, Denison JC, Atkin CL, Gregory MC (1997). Common ancestry of three Ashkenazi-American families with Alport syndrome and COL4A5 R1677Q. Hum Genet, 99(5), 681-4. (Read full article)
    28. Sprung RF, Cataldo RM, Gregory MC, Marks ML, Bull DA, Litwin SE (1996). Ruptured sinus of Valsalva aneurysm in a patient with autosomal dominant polycystic kidney disease. West J Med, 165(6), 379-82. (Read full article)
    29. Barker DF, Pruchno CJ, Jiang X, Atkin CL, Stone EM, Denison JC, Fain PR, Gregory MC (1996). A mutation causing Alport syndrome with tardive hearing loss is common in the western United States. Am J Hum Genet, 58(6), 1157-65. (Read full article)
    30. Barker DF, Atkin CL, Gregory MC, Fain PR (1996). Application of linked markers for genetic diagnosis of Alport syndrome. Contrib Nephrol, 117, 29-45. (Read full article)
    31. Gregory MC, Terreros DA, Barker DF, Fain PN, Denison JC, Atkin CL (1996). Alport syndrome--clinical phenotypes, incidence, and pathology. Contrib Nephrol, 117, 1-28. (Read full article)
    32. Heiskari N, Zhang X, Zhou J, Leinonen Anu, Barker D, Gregory M, Atkin C, Netzer KO, Weber M, Reeders S, Grnhagen-Riska C, Neumann H, Trembath R, Tryggvason K (1996). Identification of 17 mutations in ten exons in the COL4A5 collagen gene, but no mutations found in four exons in COL4A6: a study of 250 patients with hematuria and suspected of having Alport syndrome. J Am Soc Nephrol, 7, 702-709.
    33. Odell TW, Gregory MC (1995). Cost of hypertension treatment. J Gen Intern Med, 10(12), 686-8. (Read full article)
    34. Wester DC, Atkin CL, Gregory MC (1995). Alport syndrome: clinical update. J Am Acad Audiol, 6(1), 73-9. (Read full article)
    35. Doyle AJ, Gregory MC, Terreros DA (1994). Percutaneous native renal biopsy: comparison of a 1.2-mm spring-driven system with a traditional 2-mm hand-driven system. Am J Kidney Dis, 23(4), 498-503. (Read full article)
    36. Bichet DG, Arthus MF, Lonergan M, Hendy GN, Paradis AJ, Fujiwara TM, Morgan K, Gregory MC, Rosenthal W, Didwania A (1993). X-linked nephrogenic diabetes insipidus mutations in North America and the Hopewell hypothesis. J Clin Invest, 92(3), 1262-8. (Read full article)
    37. Cheung AK, DeVault GA Jr, Gregory MC (1993). A prospective study on treatment of hypercholesterolemia with lovastatin in renal transplant patients receiving cyclosporine. J Am Soc Nephrol, 3(12), 1884-91. (Read full article)
    38. Zhou J, Gregory MC, Hertz JM, Barker DF, Atkin C, Spencer ES, Tryggvason K (1993). Mutations in the codon for a conserved arginine-1563 in the COL4A5 collagen gene in Alport syndrome. Kidney Int, 43(3), 722-9. (Read full article)
    39. Cheung AK, DeVault GA, Gregory MC (1993). A prospective study on treatment of hypercholesterolemia with lovastatin in renal transplant patients receiving cyclosporine. J Am Soc Nephrol, 31, 1884-1891.
    40. Christensen AJ, Smith TW, Turner CW, Holman JM Jr, Gregory MC, Rich MA (1992). Family support, physical impairment, and adherence in hemodialysis: an investigation of main and buffering effects. J Behav Med, 15(4), 313-25. (Read full article)
    41. Bichet DG, Hendy GN, Lonergan M, Arthus M-F, Ligier S, Pausova Z, Kluge R, Zingg H, Saenger P, Oppenheimer E, Hirsch DJ, Gilgenkrantz S, Salles J-P, Oberl I, Mandel J-L, Gregory MC, Fujiwara M, Morgan K, Scriver CR (1992). X-linked nephrogenic diabetes insipidus: from the ship Hopewell to RFLP studies. Am J Hum Genet, 51, 1089-1092.
    42. Barker DF, Fain PR, Goldgar DE, Dietz-Band JN, Turco AE, Kashtan CE, Gregory MC, Tryggvason K, Skolnick MH, Atkin CL (1991). High-density genetic and physical mapping of DNA markers near the X-linked Alport syndrome locus: definition and use of flanking polymorphic markers. Hum Genet, 88(2), 189-94. (Read full article)
    43. Christensen AJ, Turner CW, Smith TW, Holman JM Jr, Gregory MC (1991). Health locus of control and depression in end-stage renal disease. J Consult Clin Psychol, 59(3), 419-24. (Read full article)
    44. Giles TD, Weber M, Bartels DW, Gregory MC, Burris JF, Due D, Sirgo MA (1991). Evaluation of labetalol in elderly patients with essential hypertension. J Clin Hypertens, 31, 556-560.
    45. Leypoldt JK, Kablitz C, Gregory MC, Senekjian HO, Cheung AK (1991). Prescribing hemodialysis using a weekly urea balance model. Blood Purif, 9, 241-245.
    46. Barker DF, Fain PR, Goldgar DE, Dietz-Bank JN, Turco AE, Kashtan CE, Gregory MC, Tryggvason K, Skolnick MH, Atkin CL (1991). High density genetic and physical mapping of DNA markers near the X-linked Alport syndrome locus: Definition and use of flanking polymorphic markers. Hum Genet, 88, 189-194.
    47. Christensen AJ, Turner CW, Smiths TW, Holman JM, Gregory MC (1991). Health locus of control and depression in chronic illness; moderating effects of treatment status and illness severity. J Consult Clin Psychol, 59, 419-424.
    48. Barker DF, Hostikka SL, Zhou J, Chow LT, Oliphant AR, Gerken SC, Gregory MC, Skolnick MH, Atkin CL, Tryggvason K (1990). Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science, 248(4960), 1224-7. (Read full article)
    49. Christensen AJ, Smith TW, Turner CW, Holman JM Jr, Gregory MC (1990). Type of hemodialysis and preference for behavioral involvement: interactive effects on adherence in end-stage renal disease. Health Psychol, 9(2), 225-36. (Read full article)
    50. Anderson CJ, Gregory MC, Groggel GC, Clegg DO (1989). Amyloidosis and Reiter's syndrome: report of a case and review of the literature. Am J Kidney Dis, 14(4), 319-23. (Read full article)
    51. Kashtan CE, Atkin CL, Gregory MC, Michael AF (1989). Identification of variant Alport phenotypes using an Alport-specific antibody probe. Kidney Int, 36(4), 669-74. (Read full article)
    52. New Zealand Glomerulonephritis Study Group et al (1989). The New Zealand glomerulonephritis study: introductory report. Clin Nephrol, 31(5), 239-246.
    53. Anderson CJ, Gregory MC, Groggel GC, Clegg DO 1989 (1989). Amyloidosis and Reiter's syndrome: report of a case and review of the literature. Am J Kidney Dis, 14(4), 319-23.
    54. Goodenough GK, Lutz LJ, Gregory MC (1988). Home-based renal dialysis. Am Fam Physician, 37(2), 203-14. (Read full article)
    55. Gregory MC, Hammond ME, Brewer ED (1988). Renal deposition of cytomegalovirus antigen in immunoglobulin-A nephropathy. Lancet, 1(8575-6), 11-4. (Read full article)
    56. Gregory MC, Micklos T, Miller FJ, Servilla KS, Nelson EW (1988). Percutaneous dilation and stenting of ureteral stenosis in renal transplantation. Clin Transplant, 2, 107-109.
    57. Terreros DA, Gregory MC (1988). Metabolic Bone Disease in Patients Undergoing Chronic Dialysis. Am Soc Clinical Path. Check Sample Continuing Education Program. Clin Chem, CC88-7, 1-4.
    58. Baker LR, Mallinson WJ, Gregory MC, Menzies EA, Cattell WR, Whitfield HN, Hendry WF, Wickham JE, Joekes AM (1987). Idiopathic retroperitoneal fibrosis. A retrospective analysis of 60 cases. Br J Urol, 60(6), 497-503. (Read full article)
    59. Taylor A Jr, Akiya F, Gregory MC (1986). Failure to visualize acutely injured kidneys with technetium-99m DMSA does not preclude recoverable function. J Nucl Med, 27(3), 377-9. (Read full article)
    60. Ekins BR, Rollins DE, Duffy DP, Gregory MC (1985). Standardized treatment of severe methanol poisoning with ethanol and hemodialysis. West J Med, 142(3), 337-40. (Read full article)
    61. Cheung AK, Gregory MC (1985). Subclavian vein thrombosis in hemodialysis patients. Trans Am Soc Artif Intern Organs, 31, 131-5. (Read full article)
    62. Smith JB, Ash KO, Gregory MC, Sprowell WL, Hentschel WM, Williams RR (1984). Hemodialysis does not affect erythrocyte sodium-lithium countertransport. Clin Chim Acta, 143(3), 275-9. (Read full article)
    63. Gregory MC, Schumann GB, Schumann JL, Argyle JC (1984). The clinical significance of candidal casts. Am J Kidney Dis, 4(2), 179-84. (Read full article)
    64. Gregory MC (1984). Acute renal failure after percutaneous cholangiography. Arch Intern Med, 144(6), 1288-9. (Read full article)
    65. Argyle C, Schumann GB, Genack L, Gregory M (1984). Identification of fungal casts in a patient with renal candidiasis. Hum Pathol, 15(5), 480-1. (Read full article)
    66. Gregory MC, Mansell MA (1983). Pregnancy and cystinuria. Lancet, 2(8360), 1158-60. (Read full article)
    67. Gregory MC, Duffy DP (1983). Toxic shock following staphylococcal peritonitis. Clin Nephrol, 20(2), 101-4. (Read full article)
    68. Cassidy M, Gregory MC, Harley EH (1980). Primary overproduction of urate caused by a partial deficiency of hypoxanthine-guanine phosphoribosyl transferase. S Afr Med J, 57(23), 948-50. (Read full article)
    69. Jacobs P, Wormald LA, Gregory MC (1979). Absorption of iron polymaltose and ferrous sulphate in rats and humans. A comparative study. S Afr Med J, 55(26), 1065-72. (Read full article)
    70. Myers HS, Gregory M, Beighton P (1979). Renal failure in a 44-year-old female. Urol Radiol, 1(4), 251-3. (Read full article)
    71. Sheppard M, Shapiro B, Pimstone B, Kronheim S, Berelowitz M, Gregory M (1979). Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man. J Clin Endocrinol Metab, 48(1), 50-3. (Read full article)
    72. Pokroy N, Ress S, Gregory MC (1977). Clofibrate-induced complications in renal disease: a case report. S Afr Med J, 52(20), 806-8. (Read full article)
    73. Gregory MC, Duval D, Meyer P (1976). Changes in cardiac and hepatic glucocorticoid receptors after adrenalectomy. Clin Sci Mol Med, 51(5), 487-93. (Read full article)
    74. Russo-Marie F, Gregory M, Ulmann A, Funck-Brentano JL (1976). [Role of sodium in the intestinal transport of calcium in idiopathic hypercalciuria]. Ann Med Interne (Paris), 127(2), 113-6. (Read full article)
    75. Gregory MC, Hughes JT (1973). Intracranial reticulum cell sarcoma associated with immunoglobulin A deficiency. J Neurol Neurosurg Psychiatry, 36(5), 769-76. (Read full article)
    76. GREGORY MC, ROBINSON JR (1965). EFFECTS OF UREA UPON THE WATER AND IONIC CONTENT OF LIVER SLICES. J Physiol, 177, 122-32. (Read full article)

    Review

    1. Savige J, Gregory M, Gross O, Kashtan C, Ding J, Flinter F (2013). Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. [Review]. J Am Soc Nephrol, 24(3), 364-75. (Read full article)
    2. Gregory MC, Shettigar UR, Kolff WJ (1984). Theoretical Value of Cascade plasmapheresis. [Review]. 5, 517-529.

    Book Chapter

    1. Gregory, MC (01/01/2014). Alport Syndrome and Related Disorders. In Gilbert, SJ; Weiner, DE; Gipson, DS; Perazella, MA;Tonelli M. (Eds.), National Kidney Foundation's Primer on Kidney Diseases (6th, pp. 375-380). Philadelphia: Elsevier Saunders.
    2. Gregory, MC (2009). Alport's Syndrome and Related Disorders. In Greenberg, A (Eds.), Primer on Kidney Diseases (5th, pp. 358-363). Philadelphia: National Kidney Foundation/Saunders.
    3. Gregory MC, Shamshirsam A, Kamgar M, Bekhernia MR (2007). Alport's Syndrome, Fabry's Disease, and Nail-Patella Syndrome. In Schrier RW (Ed.), Diseases of the Kidney (8th Edition, pp. 540-569). Boston: Little Brown.
    4. Alverson DC, Saiki SM Jr, Caudell TP, Goldsmith T, Stevens S, Saland L, Colleran K, Brandt J, Danielson L, Cerilli L, Harris A, Gregory MC, Stewart R, Norenberg J, Shuster G, Panaoitis, Holten J 3rd, Vergera VM, Sherstyuk A, Kihmm K, Lui J, Wang KL (2006). Reification of Abstract Concepts to Improve Comprehension Using Interactive Virtual Environments and a Knowledge-based Design: A Renal Physiology Model. In Westwood JD, Haluck RS, Hoffman HM, Mogel GT, Phillips R, Rob RA, Vosburgh KG (Eds.), Medicine Meets Virtual Reality 14; Accelerating Change in Health Care: Next Medical Toolkit, Volume IV Studies in Health Technology and Informatics (pp. 13-18). Amsterdam, The Netherlands: IOS Press.
    5. Gregory MD, Strong MB (2005). Manifestations and Pathophysiology. In Beringer P (Ed.), Remington's Pharmacuetical Sciences (21, pp. 1095-1141).
    6. Gregory MC (2005). Alport's Syndrome and Related Disorders. In Greenberg A (Ed.), A Primer on Kidney Diseases (4, pp. 363-367). New York: National Kidney Foundation.
    7. Gregory MC (2001). Urinalysis. In Jones SL (Ed.), Clinical Laboratory Pearls (pp. 326-336). Philadelphia: Lippincott Williams and Wilkins.
    8. Gregory MC (2001). Renal Function Tests. In Jones SL (Ed.), Clinical Laboratory Pearls (pp. 319-325). Philadelphia: Lippincott Williams and Wilkins.
    9. Gregory MC (2001). Alport's Syndrome and Related Disorders. In Greenberg A (Ed.), A Primer of Kidney Diseases (3rd Ed, pp. 308-312). National Kidney Foundation.
    10. Gregory MC (2001). Alport's Syndrome. In Schrier RW, Gottschalk CW (Eds.), Diseases of the Kidney (7th Ed, pp. 589-619). Little Brown, Boston.
    11. Gregory MC, Tolman KG (2000). Diseases: Manifestations and Pathophysiology. In Gennaro AR et al (Ed.), Remington's Pharmaceutical Sciences (20th Ed, pp. 1053-1097).
    12. Gregory MC (1997). Alport's Syndrome. In O'Kane P (Ed.), Companion to Kelley's Textbook of Internal Medicine (pp. 107-108). Philadelphia: Lippincott-Raven.
    13. Gregory MC, Atkin CL (1997). Hereditary nephropathies. In Kelley WM (Ed.), Textbook of Internal Medicine (3rd Ed, pp. 1018-1020). Philadelphia: Lippincott.
    14. Gregory MC, Atkin CL (1997). Alport's Syndrome, Fabry's Disease, and Nail-Patella Syndrome. In Schrier RW, Gottschalk CW (Eds.), Diseases of the Kidney (6th Ed, pp. 561-590). Little Brown, Boston.
    15. Gregory MC (1997). Alport's Syndrome and Related Disorders. In Greenberg A (Ed.), Primer on Kidney Diseases (2nd Ed, pp. 318-323). National Kidney Foundation.
    16. Barker DF, Atkin CL, Fain PR, Gregory MC (1996). Clinical genetics and linkage markers in diagnosis of Alport Syndrome. In Tryggvason K (Ed.), Molecular Pathology and Genetics of Alport Syndrome (117, pp. 29-45). Contrib Nephrol Basel.
    17. Gregory MC, Terreros DA, Barker DF, Fain PR, Atkin CL (1996). Alport syndrome--clinical phenotypes, incidence, and pathology. In Tryggvason K (Ed.), Molecular Pathology and Genetics of Alport Syndrome (117, pp. 1-28). Contrib Nephrol Basel.
    18. Gregory MC, Morgan SH (1994). Fabry's Disease. In Greenberg A (Ed.), A Primer of Nephrology (pp. 206-210). National Kidney Foundation.
    19. Gregory MC (1994). Alport's Syndrome and Related Disorders. In Greenberg A (Ed.), A Primer of Nephrology (pp. 211-212). National Kidney Foundation.
    20. Gregory MC, Atkin CL (1993). Alport Syndrome. In Schrier RW, Gottschalk CW (Eds.), Diseases of the Kidney (pp. 571-591). Little Brown, Boston.
    21. Gregory MC, Atkin CL (1992). Hereditary nephropathies. In Kelley WM (Ed.), Textbook of Internal Medicine (2nd Ed, pp. 736-738). Philadelphia: Lippincott.
    22. Gregory MC (1992). Alport's Syndrome and related hereditary nephritides. In Andreucci VE, Fine LG (Eds.) (pp. 143-156).
    23. Atkin CL, Gregory MC, Border WA (1988). Alport Syndrome. In Schrier RW, Gottschalk CW (Eds.), Diseases of the Kidney (4th Ed., pp. 617-641). Little Brown, Boston.
    24. Gregory MC, Border WA, Atkin CL (1988). Hereditary nephropathies. In Kelley WM (Ed.), Textbook of Internal Medicine (pp. 791-793). Philadelphia: Lippincott.
    25. Gregory MC (1988). Artificial Kidney. In Webster JG (Ed.), Encyclopedia of Medical Devices and Instrumentation (3, pp. 1695-1712). New York: Wiley.
    26. Shettigar UR, Gregory MC, Kolff WJ (1987). Mathematical analysis of renal disease progression. In Andrade JD, Brophy JJ, Detmer DE, et al (Eds.), Artif Organs (pp. 279-291). New York: VCH publishers.
    27. Fraser AK, Gregory MC, Rose GA, Samuell CT (1985). A study of factors affecting urinary citrate levels. In Schwille PO, Smith LH, Robertson WG, Wahlensieck W (Eds.), Urolithiasis and Related Clinical Research (pp. 249-252). New York: Plenum Press.
    28. Gregory MC (1978). Acid-base regulation. In Basic Medical Sciences (pp. 28-32). Cape Town: UCT Press.

    Conference Proceedings

    1. Davies-Jones GAB, Gregory MC, Whitty CWM (1973). Permanent sequelae in the migraine attack. Background to Migraine, London: Heinemann, 5, 25-27.

    Editorial

    1. Gregory MC (2004). Alport syndrome and thin basement membrane nephropathy: unraveling the tangled strands of type IV collagen. Kidney Int, 65(3), 1109-10. (Read full article)

    Letter

    1. Solez K, Daugirdas J, Gregory MC, Frohnert PP, Bhowmik DM, Jha V, Cosyns JP (2001). Is "Chinese herbs nephropathy" a prejudicial term? [Letter to the editor]. Am J Kidney Dis, 38(5), 1141-2. (Read full article)
    2. Gregory MC (1985). Comparing US and other homicide rates. [Letter to the editor]. West J Med, 143(3), 389-90. (Read full article)
    3. Kinniburgh DW, Ash KO, Gregory MC (1983). Should routine microscopic examination of urine be discontinued? [Letter to the editor]. Clin Chem, 29(1), 212-3. (Read full article)
    4. Gottheiner TI, Pokroy N, Gregory MC (1977). Herpes zoster with bladder involvement. [Letter to the editor]. Lancet, 1(8010), 551. (Read full article)

    Other

    1. Savige J, Storey H, Watson E, Hertz JM, Deltas C, Renieri A, Mari F, Hilbert P, Plevova P, Byers P, Cerkauskaite A, Gregory M, Cerkauskiene R, Ljubanovic DG, Becherucci F, Errichiello C, Massella L, Aiello V, Lennon R, Hopkinson L, Koziell A, Lungu A, Rothe HM, Hoefele J, Zacchia M, Martic TN, Gupta A, van Eerde A, Gear S, Landini S, Palazzo V, Al-Rabadi L, Claes K, Corveleyn A, Van Hoof E, van Geel M, Williams M, Ashton E, Belge H, Ars E, Bierzynska A, Gangemi C, Lipska-Zitkiewicz BS (2023). Correction: Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria. Eur J Hum Genet. England. (Read full article)